Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical-stage biopharmaceutical company that is focused on developing and commercializing products for the treatment of ADHD and anxiety. Their initial focus is on the development of two proprietary first-line stimulant medications for ADHD in both children and adults. The company has a large market potential with millions of potential patients and strong growth in the ADHD medication market. Current valuation is attractive with significant upside potential, but there are risks to attaining their price target. A potential approval in mid or late 2026 could be a strong positive catalyst for the stock.

Bears say

Cingulate is facing potential challenges with gaining FDA approval for their first-line stimulant medications, CTx-1301 and CTx-1302, due to receiving a CRL that requires additional CMC information. However, their utilization of PTR technology shows promise for a once-daily, multi-dose tablet, and with no safety or efficacy concerns, the company has potential for FDA approval. While the recent Q4 results showed a net loss and no guidance, the company's recent stock raise provides enough cash to sustain operations until mid-2027.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.